Safety, Immunogenicity and Reactogenicity Trial of Mencevax ACW135 Vaccine

PHASE2CompletedINTERVENTIONAL
Enrollment

412

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

January 31, 2006

Study Completion Date

November 30, 2007

Conditions
Meningococcal Meningitis
Interventions
BIOLOGICAL

Mencevax ACW Vaccine

Mencevax ACW polysaccharide vaccine subcutaneously in the left arm at 50 μg in 0.5ml(reconstituted).

Trial Locations (1)

Unknown

Butajira Hospital, Butajīra

All Listed Sponsors
collaborator

World Health Organization

OTHER

collaborator

Addis Ababa University

OTHER

collaborator

London School of Hygiene and Tropical Medicine

OTHER

lead

Armauer Hansen Research Institute, Ethiopia

OTHER

NCT00994695 - Safety, Immunogenicity and Reactogenicity Trial of Mencevax ACW135 Vaccine | Biotech Hunter | Biotech Hunter